Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin.
To study the functional consequences of various cardiomyopathic mutations in human cardiac alpha-tropomyosin (Tm), a method of depletion/reconstitution of native Tm and troponin (Tn) complex (Tm-Tn) in cardiac myofibril preparations has been developed. The endogenous Tm-Tn complex was selectively removed from myofibrils and replaced with recombinant wild-type or mutant proteins. Successful depletion and reconstitution steps were verified by SDS-gel electrophoresis and by the loss and regain of Ca2+-dependent regulation of ATPase activity. Five Tm mutations were chosen for this study: the hypertrophic cardiomyopathy (HCM) mutations E62Q, E180G, and L185R and the dilated cardiomyopathy (DCM) mutations E40K and E54K. Through the use of this new depletion/reconstitution method, the functional consequences of these mutations were determined utilizing myofibrillar ATPase measurements. The results of our studies showed that 1) depletion of >80% of Tm-Tn from myofibrils resulted in a complete loss of the Ca2+-regulated ATPase activity and a significant loss in the maximal ATPase activity, 2) reconstitution of exogenous wild-type Tm-Tn resulted in complete regain in the calcium regulation and in the maximal ATPase activity, and 3) all HCM-associated Tm mutations increased the Ca2+ sensitivity of ATPase activity and all had decreased abilities to inhibit ATPase activity. In contrast, the DCM-associated mutations both decreased the Ca2+ sensitivity of ATPase activity and had no effect on the inhibition of ATPase activity. These findings have demonstrated that the mutations which cause HCM and DCM disrupt discrete mechanisms, which may culminate in the distinct cardiomyopathic phenotypes.
Chang
Audrey N
AN
Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Harada
Keita
K
Ackerman
Michael J
MJ
Potter
James D
JD
D000251:Adenosine Triphosphatases / Q000032:analysis / Q000378:metabolism*; D002311:Cardiomyopathy, Dilated / Q000235:genetics*; D004252:DNA Mutational Analysis; D005818:Genetic Engineering; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000235:genetics*; D017380:Hypertrophy, Right Ventricular / Q000235:genetics*; D009210:Myofibrils / Q000737:chemistry; D010641:Phenotype; D014335:Tropomyosin / Q000235:genetics*; D014336:Troponin / Q000235:genetics*
D014335:Tropomyosin; D014336:Troponin; D000251:Adenosine Triphosphatases